Grattoni, A. et al. Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead. Nat. Rev. Endocrinol. 21, 14–30 (2025).
Google Scholar
Bluestone, J. A., Buckner, J. H. & Herold, K. C. Immunotherapy: building a bridge to a cure for type 1 diabetes. Science 373, 510–516 (2021).
Google Scholar
Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603–613 (2019).
Google Scholar
Warshauer, J. T., Bluestone, J. A. & Anderson, M. S. New frontiers in the treatment of type 1 diabetes. Cell Metab. 31, 46–61 (2020).
Google Scholar
Xiao, Y. et al. Fatty acid binding protein 4 promotes autoimmune diabetes by recruitment and activation of pancreatic islet macrophages. JCI Insight 6, e141814 (2021).
Google Scholar
Gur, C. et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat. Immunol. 11, 121–128 (2010).
Google Scholar
Gomez-Muñoz, L. et al. NK cell subsets changes in partial remission and early stages of pediatric type 1 diabetes. Front. Immunol. 11, 611522 (2020).
Google Scholar
Dean, J. W. et al. Innate inflammation drives NK cell activation to impair Treg activity. J. Autoimmun. 108, 102417 (2020).
Google Scholar
Xhonneux, L. P. et al. Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression. Sci. Transl. Med. 13, eabd5666 (2021).
Google Scholar
Ogasawara, K. et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20, 757–767 (2004).
Google Scholar
Beilke, J. N. et al. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS ONE 7, e36011 (2012).
Google Scholar
Herold, K. C. et al. The immunology of type 1 diabetes. Nat. Rev. Immunol. 24, 435–451 (2024).
Google Scholar
Rebuffet, L. et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat. Immunol. 25, 1474–1488 (2024).
Google Scholar
Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235–4251.e20 (2023).
Google Scholar
Zhong, T. et al. The remission phase in type 1 diabetes: changing epidemiology, definitions, and emerging immuno-metabolic mechanisms. Diabetes Metab. Res. Rev. 36, e3207 (2020).
Google Scholar
Gomez-Muñoz, L., Dominguez-Bendala, J., Pastori, R. L. & Vives-Pi, M. Immunometabolic biomarkers for partial remission in type 1 diabetes mellitus. Trends Endocrinol. Metab. 35, 151–163 (2024).
Google Scholar
Li, X. et al. PD-1 and PD-L1 Expression in peripheral CD4/CD8+ T cells is restored in the partial remission phase in type 1 diabetes. J. Clin. Endocrinol. Metab. 105, dgaa130 (2020).
Google Scholar
Zhong, T. et al. CXCL12–CXCR4 mediates CD57+ CD8+ T cell responses in the progression of type 1 diabetes. J. Autoimmun. 143, 103171 (2024).
Google Scholar
Zhong, T. et al. TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes. Nat. Commun. 15, 8894 (2024).
Google Scholar
Crinier, A. et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity 49, 971–986.e5 (2018).
Google Scholar
Di Vito, C., Mikulak, J. & Mavilio, D. On the way to become a natural killer cell. Front. Immunol. 10, 1812 (2019).
Google Scholar
Gulati, G. S. et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science 367, 405–411 (2020).
Google Scholar
Thacker, G. et al. Immature natural killer cells promote progression of triple-negative breast cancer. Sci. Transl. Med. 15, eabl4414 (2023).
Google Scholar
Zakharov, P. N., Hu, H., Wan, X. & Unanue, E. R. Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes. J. Exp. Med. 217, e20192362 (2020).
Google Scholar
Jiang, P. et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat. Methods 18, 1181–1191 (2021).
Google Scholar
Martinet, L. & Smyth, M. J. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243–254 (2015).
Google Scholar
Briukhovetska, D. et al. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity 56, 143–161.e11 (2023).
Google Scholar
Hsieh, W. C. et al. NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. J. Clin. Invest. 131, e146408 (2021).
Google Scholar
Martinet, L. et al. DNAM-1 expression marks an alternative program of NK cell maturation. Cell Rep. 11, 85–97 (2015).
Google Scholar
Stannard, K. A. et al. Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Adv. 3, 1681–1694 (2019).
Google Scholar
Crinier, A., Narni-Mancinelli, E., Ugolini, S. & Vivier, E. SnapShot: natural killer cells. Cell 180, 1280–1280.e1 (2020).
Google Scholar
Glaviano, A. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).
Google Scholar
Chou, W. C., Rampanelli, E., Li, X. & Ting, J. P. Impact of intracellular innate immune receptors on immunometabolism. Cell. Mol. Immunol. 19, 337–351 (2022).
Google Scholar
Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325–338 (2012).
Google Scholar
Jeong, W. I., Park, O., Radaeva, S. & Gao, B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441–1451 (2006).
Google Scholar
Gotthardt, D. et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124, 2370–2379 (2014).
Google Scholar
Sutherland, A. P. et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 58, 1144–1155 (2009).
Google Scholar
Ferreira, R. C. et al. IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia 58, 781–790 (2015).
Google Scholar
Rydén, A. K. et al. Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes. J. Autoimmun. 84, 65–74 (2017).
Google Scholar
von Herrath, M. et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 212–224 (2021).
Google Scholar
Van Belle, T. L., Nierkens, S., Arens, R. & von Herrath, M. G. Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 36, 1060–1072 (2012).
Google Scholar
Duurland, C. L. et al. CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. J. Immunother. Cancer 10, e003995 (2022).
Google Scholar
Kleinschek, M. A. et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206, 525–534 (2009).
Google Scholar
Liu, R. et al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J. Immunol. 176, 5247–5254 (2006).
Google Scholar
Parrish-Novak, J. et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57–63 (2000).
Google Scholar
Seyedsadr, M. et al. A pathologically expanded, clonal lineage of IL-21-producing CD4+ T cells drives inflammatory neuropathy. J. Clin. Invest. 134, e178602 (2024).
Google Scholar
Suto, A. et al. Development and characterization of IL-21-producing CD4+ T cells. J. Exp. Med. 205, 1369–1379 (2008).
Google Scholar
Braun, M. et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity 53, 805–823.e15 (2020).
Google Scholar
Brown, M. E. et al. Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes. Sci. Adv. 11, eadx9755 (2025).
Google Scholar
American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: standards of care in diabetes—2024. Diabetes Care 47, S20–S42 (2024).
Google Scholar
Mortensen, H. B. et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32, 1384–1390 (2009).
Google Scholar
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
Google Scholar
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
Google Scholar
Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).
Google Scholar
Jin, S. et al. Inference and analysis of cell–cell communication using CellChat. Nat. Commun. 12, 1088 (2021).
Google Scholar
Linderman, G. C. et al. Zero-preserving imputation of single-cell RNA-seq data. Nat. Commun. 13, 192 (2022).
Google Scholar
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Google Scholar
McGuire, H. M. et al. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 60, 867–875 (2011).
Google Scholar
